GNI Group closes share price forward contract, reports loss

GNI Group (TSE:2160) announced the completion of its share price forward contract transaction with Macquarie, initiated in 2024 to address excessive liquidity. The company decided to terminate the program in 2025 to focus resources on its core biopharmaceutical business. Macquarie closed its position per the contract terms; GNI Group stated it had no control over the sale method or timing. The contract’s closure, coinciding with global market declines and increased stock volatility, led to a loss of ¥483 million for GNI Group. The company aims to enhance shareholder value by driving sales, profitability, and pipeline product development.